# Martin Wermke

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/martin-wermke/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,566 |
| Field | CAR-T cell therapy research |
| h-index | 44 |
| i10-index | 109 |
| Last Known Institution | Heidelberg University |
| OpenAlex ID | https://openalex.org/A5034434819 |
| ORCID iD | 0000-0002-4844-4087 |
| Works | 318 |

## Researcher papers

- [Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis](https://scholariq.org/papers/analysis-of-flt3-activating-mutations-in-979-patients-with-acute-myelogenous/)
- [Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial](https://scholariq.org/papers/azacitidine-for-treatment-of-imminent-relapse-in-mds-or-aml-patients-after/)
- [Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia](https://scholariq.org/papers/distribution-and-levels-of-cell-surface-expression-of-cd33-and-cd123-in-acute/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia](https://scholariq.org/papers/flotetuzumab-as-salvage-immunotherapy-for-refractory-acute-myeloid-leukemia/)
- [Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial](https://scholariq.org/papers/ramucirumab-plus-pembrolizumab-in-patients-with-previously-treated-advanced-non/)
- [Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms](https://scholariq.org/papers/phase-i-first-in-human-dose-escalation-study-of-the-oral-sf3b1-modulator-h3b/)
- [A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial](https://scholariq.org/papers/a-novel-prognostic-model-in-elderly-patients-with-acute-myeloid-leukemia-results/)
- [Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial](https://scholariq.org/papers/avelumab-in-patients-with-previously-treated-metastatic-adrenocortical-carcinoma/)
- [Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML](https://scholariq.org/papers/proof-of-concept-for-a-rapidly-switchable-universal-car-t-platform-with-unicar-t/)
- [1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy](https://scholariq.org/papers/1336p-small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-egfr/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Heidelberg University](https://scholariq.org/institutions/heidelberg-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.